Similar Products:
| Image | Product | Manufacturer / Marketed By | Price |
|---|---|---|---|
 | Posid 50 mg Capsule | Cadila Pharmaceuticals Ltd | Ask for Price |
| Etoplast 50 mg Capsule | N/A | Ask for Price |
 | Vepesid Injection | Bristol Myers Squibb | Ask for Price |
Benefits
-
Slows or stops cancer cell growth
-
Effective as part of combination chemotherapy regimens
-
Improves treatment response and survival outcomes
-
Oral capsule offers convenient administration
Indications and Usage
Adside Etoposide 50mg Capsule is indicated for:
-
Small Cell Lung Cancer (SCLC)
-
Testicular Cancer
-
May be used in other solid tumors or hematologic cancers as prescribed
Treatment must be initiated and supervised by an oncology specialist.
How it Works
Etoposide blocks topoisomerase II, an enzyme cancer cells need for DNA replication. This prevents cell division and leads to cancer cell death, helping slow tumor growth.
Dosage & Administration
-
Typical dose: based on body surface area (BSA) and treatment plan
-
Usually taken once or twice daily for several days in a chemotherapy cycle
-
Swallow capsules whole with water—do not crush or chew
-
Can be taken with or without food, unless advised otherwise
-
Do not stop or change the dose without medical guidance
-
Routine blood tests required to monitor counts and organ function
Use only under oncologist supervision.
Side Effects
Common side effects:
-
Nausea, vomiting
-
Loss of appetite
-
Fatigue or weakness
-
Hair loss
-
Low blood cell counts
Serious side effects (seek urgent care):
-
Severe infection or fever
-
Unusual bleeding or bruising
-
Allergic reactions
-
Liver dysfunction
-
Severe stomach or chest pain
Warning and Precaution
-
Not recommended during pregnancy or breastfeeding
-
May cause severe bone marrow suppression—monitor blood counts regularly
-
Inform doctor if you have liver, kidney, or heart disease
-
Increased infection and bleeding risk
-
Avoid live vaccines during treatment
-
Report fever, bleeding, shortness of breath, or jaundice immediately
Related Products
Related Posts:
Ruxolitinib Tablets Receive FDA Approval for Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) has approved Ruxolitinib tablets for the treatment of certain hematologic malignancies, marking another
READ MORE »May 18, 2026
Tovorafenib Approved in Europe for Children with BRAF-Altered Low-Grade Glioma
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 14, 2026.n n This marks an important
READ MORE »May 14, 2026
FDA Fast-Tracks Plixorafenib for BRAF V600E–Mutated Brain Tumors
n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 14, 2026.n n Brain tumors, especially high-grade
READ MORE »April 14, 2026
Only logged in customers who have purchased this product may leave a review.
Reviews
Clear filtersThere are no reviews yet.